LIU, Yusi. How do varying concentrations and treatment durations of anti-PDL1 antibodies affect HCT116 cell viability, xenograft tumor size, and T cell activation, as measured by MTT assay, tumor weight, and IL-2 production, respectively?. MedScien, [S. l.], v. 2, n. 6, p. 2912, 2024. DOI: 10.61173/n49rc157. Disponível em: https://ms.deanfrancis.press/article/view/1005. Acesso em: 4 nov. 2026.